Literature DB >> 24047273

Therapeutic strategies impacting cancer cell glutamine metabolism.

Michael J Lukey1, Kristin F Wilson, Richard A Cerione.   

Abstract

The metabolic adaptations that support oncogenic growth can also render cancer cells dependent on certain nutrients. Along with the Warburg effect, increased utilization of glutamine is one of the metabolic hallmarks of the transformed state. Glutamine catabolism is positively regulated by multiple oncogenic signals, including those transmitted by the Rho family of GTPases and by c-Myc. The recent identification of mechanistically distinct inhibitors of glutaminase, which can selectively block cellular transformation, has revived interest in the possibility of targeting glutamine metabolism in cancer therapy. Here, we outline the regulation and roles of glutamine metabolism within cancer cells and discuss possible strategies for, and the consequences of, impacting these processes therapeutically.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24047273      PMCID: PMC4154374          DOI: 10.4155/fmc.13.130

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  122 in total

1.  Targeting cell metabolism in cancer patients.

Authors:  Matthew G Vander Heiden
Journal:  Sci Transl Med       Date:  2010-05-12       Impact factor: 17.956

2.  Glutamine uptake and metabolism are coordinately regulated by ERK/MAPK during T lymphocyte activation.

Authors:  Erikka L Carr; Alina Kelman; Glendon S Wu; Ravindra Gopaul; Emilee Senkevitch; Anahit Aghvanyan; Achmed M Turay; Kenneth A Frauwirth
Journal:  J Immunol       Date:  2010-06-16       Impact factor: 5.422

3.  Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species.

Authors:  Sawako Suzuki; Tomoaki Tanaka; Masha V Poyurovsky; Hidekazu Nagano; Takafumi Mayama; Shuichi Ohkubo; Maria Lokshin; Hiroyuki Hosokawa; Toshinori Nakayama; Yutaka Suzuki; Sumio Sugano; Eiichi Sato; Toshitaka Nagao; Koutaro Yokote; Ichiro Tatsuno; Carol Prives
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

4.  Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity.

Authors:  Frank Weinberg; Robert Hamanaka; William W Wheaton; Samuel Weinberg; Joy Joseph; Marcos Lopez; Balaraman Kalyanaraman; Gökhan M Mutlu; G R Scott Budinger; Navdeep S Chandel
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-26       Impact factor: 11.205

5.  Ammonia derived from glutaminolysis is a diffusible regulator of autophagy.

Authors:  Christina H Eng; Ker Yu; Judy Lucas; Eileen White; Robert T Abraham
Journal:  Sci Signal       Date:  2010-04-27       Impact factor: 8.192

6.  Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function.

Authors:  Wenwei Hu; Cen Zhang; Rui Wu; Yvonne Sun; Arnold Levine; Zhaohui Feng
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-08       Impact factor: 11.205

Review 7.  O-GlcNAc signaling in the cardiovascular system.

Authors:  Gladys A Ngoh; Heberty T Facundo; Ayesha Zafir; Steven P Jones
Journal:  Circ Res       Date:  2010-07-23       Impact factor: 17.367

8.  Metabolic modulation of glioblastoma with dichloroacetate.

Authors:  E D Michelakis; G Sutendra; P Dromparis; L Webster; A Haromy; E Niven; C Maguire; T-L Gammer; J R Mackey; D Fulton; B Abdulkarim; M S McMurtry; K C Petruk
Journal:  Sci Transl Med       Date:  2010-05-12       Impact factor: 17.956

Review 9.  Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer.

Authors:  R J DeBerardinis; T Cheng
Journal:  Oncogene       Date:  2009-11-02       Impact factor: 9.867

10.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.

Authors:  Lenny Dang; David W White; Stefan Gross; Bryson D Bennett; Mark A Bittinger; Edward M Driggers; Valeria R Fantin; Hyun Gyung Jang; Shengfang Jin; Marie C Keenan; Kevin M Marks; Robert M Prins; Patrick S Ward; Katharine E Yen; Linda M Liau; Joshua D Rabinowitz; Lewis C Cantley; Craig B Thompson; Matthew G Vander Heiden; Shinsan M Su
Journal:  Nature       Date:  2009-12-10       Impact factor: 49.962

View more
  51 in total

Review 1.  The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease.

Authors:  Tamina Seeger-Nukpezah; Daniel M Geynisman; Anna S Nikonova; Thomas Benzing; Erica A Golemis
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

2.  Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism.

Authors:  Qingqiu Huang; Clint Stalnecker; Chengliang Zhang; Lee A McDermott; Prema Iyer; Jason O'Neill; Shawn Reimer; Richard A Cerione; William P Katt
Journal:  J Biol Chem       Date:  2018-01-09       Impact factor: 5.157

3.  An anti-ASCT2 monoclonal antibody suppresses gastric cancer growth by inducing oxidative stress and antibody dependent cellular toxicity in preclinical models.

Authors:  Aya Osanai-Sasakawa; Kenta Hosomi; Yoshiki Sumitomo; Takuya Takizawa; Shiho Tomura-Suruki; Minami Imaizumi; Noriyuki Kasai; Tze Wei Poh; Kazuya Yamano; Wei Peng Yong; Koji Kono; Satoshi Nakamura; Toshihiko Ishii; Ryuichiro Nakai
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

4.  Conformational changes in the activation loop of mitochondrial glutaminase C: A direct fluorescence readout that distinguishes the binding of allosteric inhibitors from activators.

Authors:  Clint A Stalnecker; Jon W Erickson; Richard A Cerione
Journal:  J Biol Chem       Date:  2017-02-14       Impact factor: 5.157

5.  Glutaminase GLS1 Inhibitors as Potential Cancer Treatment.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2016-02-01       Impact factor: 4.345

Review 6.  Metabolism and immunity in breast cancer.

Authors:  Deyu Zhang; Xiaojie Xu; Qinong Ye
Journal:  Front Med       Date:  2020-10-19       Impact factor: 4.592

Review 7.  Targeting amino acid metabolism for cancer therapy.

Authors:  Michael J Lukey; William P Katt; Richard A Cerione
Journal:  Drug Discov Today       Date:  2016-12-14       Impact factor: 7.851

8.  Radiosynthesis, in vitro and preliminary in vivo evaluation of the novel glutamine derived PET tracers [18F]fluorophenylglutamine and [18F]fluorobiphenylglutamine.

Authors:  Tristan Baguet; Jeroen Verhoeven; Glenn Pauwelyn; Jiyun Hu; Patricia Lambe; Stef De Lombaerde; Sarah Piron; Sam Donche; Benedicte Descamps; Ingeborg Goethals; Christian Vanhove; Filip De Vos; M Hassan Beyzavi
Journal:  Nucl Med Biol       Date:  2020-04-03       Impact factor: 2.408

Review 9.  Metabolic Alterations in Cancer and Their Potential as Therapeutic Targets.

Authors:  Jamie D Weyandt; Craig B Thompson; Amato J Giaccia; W Kimryn Rathmell
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

Review 10.  Arginine depriving enzymes: applications as emerging therapeutics in cancer treatment.

Authors:  Neha Kumari; Saurabh Bansal
Journal:  Cancer Chemother Pharmacol       Date:  2021-07-26       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.